News | October 13, 2022
Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Funds raised will be used to develop technology and foster healthcare partnerships
The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
The campaign will also focus on providing doorstep TB screening services to facilitate diagnosis
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery
Subscribe To Our Newsletter & Stay Updated
